{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:12:07Z","timestamp":1789567927057,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274268"],"award-info":[{"award-number":["82274268"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Scientific Research\u00a0Program for\u00a0Young\u00a0and Middle-aged Health Professionals of\u00a0Fujian Province,China","award":["2022ZQNZD002"],"award-info":[{"award-number":["2022ZQNZD002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Radiotherapy (RT) is an effective and available local treatment for patients with refractory or relapsed (R\/R) aggressive B-cell lymphomas. However, the value of hypofractionated RT in this setting has not been confirmed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed patients with R\/R aggressive B-cell lymphoma who received hypofractionated RT between January 2020 and August 2022 at a single institution. The objective response rate (ORR), overall survival (OS), progression-free survival (PFS) and acute side effects were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 30 patients were included. The median dose for residual disease was 36\u00a0Gy, at a dose per fraction of 2.3\u20135\u00a0Gy. After RT, the ORR and complete response (CR) rates were 90% and 80%, respectively. With a median follow-up of 10\u00a0months (range, 2\u201327\u00a0months), 10 patients (33.3%) experienced disease progression and three died. The 1-year OS and PFS rates for all patients were 81.8% and 66.3%, respectively. The majority (8\/10) of post-RT progressions involved out-of-field relapses. Patients with relapsed diseases, no response to systemic therapy, multiple lesions at the time of RT, and no response to RT were associated with out-of-field relapses. PFS was associated with response to RT (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001) and numbers of residual sites (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). No serious non-hematological adverse effects (\u2265\u2009grade 3) associated with RT were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These data suggest that hypofractionated RT was effective and tolerable for patients with R\/R aggressive B-cell lymphoma, especially for those that exhibited localized residual disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-024-11837-2","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T08:01:53Z","timestamp":1705132913000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era"],"prefix":"10.1186","volume":"24","author":[{"given":"Cheng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Lan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Yan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Zhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Qing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Qin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Ying","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"key":"11837_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842\u201358.","journal-title":"N Engl J Med"},{"key":"11837_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443\u201359.","journal-title":"CA Cancer J Clin"},{"key":"11837_CR3","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood.2021013998","volume":"139","author":"EA Hawkes","year":"2022","unstructured":"Hawkes EA, Barraclough A, Sehn LH. Limited-stage diffuse large B-cell lymphoma. Blood. 2022;139:822\u201334.","journal-title":"Blood"},{"key":"11837_CR4","doi-asserted-by":"publisher","first-page":"e838","DOI":"10.1016\/S2352-3026(20)30222-2","volume":"7","author":"JK Lue","year":"2020","unstructured":"Lue JK, O\u2019Connor OA. A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise. The Lancet Haematology. 2020;7:e838\u201350.","journal-title":"The Lancet Haematology"},{"key":"11837_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya S, Barta SK. 2021 Update on Diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96:617\u201329.","journal-title":"Am J Hematol"},{"key":"11837_CR6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMc1800913","volume":"378","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Locke FL, Go WY. CAR T-cell therapy in large B-Cell lymphoma. N Engl J Med. 2018;378:1065.","journal-title":"N Engl J Med"},{"key":"11837_CR7","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood"},{"key":"11837_CR8","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","volume":"103","author":"T Kewalramani","year":"2004","unstructured":"Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684\u20138.","journal-title":"Blood"},{"key":"11837_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.1998.16.1.63","volume":"16","author":"U Popat","year":"1998","unstructured":"Popat U, Przepiork D, Champlin R, et al. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol. 1998;16:63\u20139.","journal-title":"J Clin Oncol"},{"key":"11837_CR10","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1016\/S2352-3026(18)30054-1","volume":"5","author":"QD Shen","year":"2018","unstructured":"Shen QD, Zhu HY, Wang L, et al. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial. Lancet Haematol. 2018;5:e261\u20139.","journal-title":"Lancet Haematol"},{"key":"11837_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/bmt.2015.286","volume":"51","author":"SP Robinson","year":"2016","unstructured":"Robinson SP, Boumendil A, Finel H, et al. Autologous stem cell transplantation for relapsed\/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT lymphoma working party. Bone Marrow Transplant. 2016;51:365\u201371.","journal-title":"Bone Marrow Transplant"},{"key":"11837_CR12","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184\u201390.","journal-title":"J Clin Oncol"},{"key":"11837_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41408-021-00485-5","volume":"11","author":"U Duhrsen","year":"2021","unstructured":"Duhrsen U, Tometten M, Kroschinsky F, et al. Phase I\/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma. Blood Cancer J. 2021;11:95.","journal-title":"Blood Cancer J"},{"key":"11837_CR14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjh.15412","volume":"182","author":"C Gisselbrecht","year":"2018","unstructured":"Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed\/refractory diffuse large B cell lymphoma. Br J Haematol. 2018;182:633\u201343.","journal-title":"Br J Haematol"},{"key":"11837_CR15","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41409-021-01264-3","volume":"56","author":"L Bento","year":"2021","unstructured":"Bento L, Gutierrez A, Novelli S, et al. Allogeneic stem cell transplantation as a curative option in relapse\/refractory diffuse large B cell lymphoma: Spanish multicenter GETH\/GELTAMO study. Bone Marrow Transplant. 2021;56:1919\u201328.","journal-title":"Bone Marrow Transplant"},{"key":"11837_CR16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/bjh.14453","volume":"176","author":"SA Vardhana","year":"2017","unstructured":"Vardhana SA, Sauter CS, Matasar MJ, et al. Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. Br J Haematol. 2017;176:591\u20139.","journal-title":"Br J Haematol"},{"key":"11837_CR17","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-Cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38:3119\u201328.","journal-title":"J Clin Oncol"},{"key":"11837_CR18","unstructured":"Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2021."},{"key":"11837_CR19","doi-asserted-by":"publisher","first-page":"109580","DOI":"10.1016\/j.radonc.2023.109580","volume":"183","author":"J Fan","year":"2023","unstructured":"Fan J, Adams A, Sieg N, et al. Potential synergy between radiotherapy and CAR T-cells - A multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy. Radiother Oncol. 2023;183:109580.","journal-title":"Radiother Oncol"},{"issue":"5","key":"11837_CR20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ijrobp.2022.12.017","volume":"116","author":"O Saifi","year":"2022","unstructured":"Saifi O, Breen WG, Lester SC, et al. Don\u2019t put the CART before the horse: the role of radiation therapy in Peri-CAR T-cell therapy for aggressive B-cell non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2022;116(5):999\u20131007.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11837_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.radonc.2021.11.031","volume":"166","author":"O Saifi","year":"2021","unstructured":"Saifi O, Breen WG, Lester SC, et al. Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-hodgkin lymphoma? Radiother Oncol. 2021;166:171\u20139.","journal-title":"Radiother Oncol"},{"key":"11837_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.radonc.2022.08.007","volume":"175","author":"HS Ababneh","year":"2022","unstructured":"Ababneh HS, Abramson JS, Johnson PC, Patel CG. Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy. Radiother Oncol. 2022;175:65\u201372.","journal-title":"Radiother Oncol"},{"key":"11837_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/bjh.16541","volume":"190","author":"BS Imber","year":"2020","unstructured":"Imber BS, Sadelain M, DeSelm C, et al. Early experience using salvage radiotherapy for relapsed\/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy. Br J Haematol. 2020;190:45\u201351.","journal-title":"Br J Haematol"},{"key":"11837_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","volume":"108","author":"CM Wright","year":"2020","unstructured":"Wright CM, LaRiviere MJ, Baron JA, et al. Bridging radiation therapy before commercial chimeric antigen receptor T-Cell therapy for relapsed or refractory aggressive B-Cell lymphoma. Int J Radiat Oncol Biol Phys. 2020;108:178\u201388.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11837_CR25","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.3324\/haematol.2023.283311","volume":"108","author":"O Saifi","year":"2023","unstructured":"Saifi O, Breen WG, Lester SC, et al. Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma. Haematologica. 2023;108:2982\u201392.","journal-title":"Haematologica"},{"key":"11837_CR26","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ijrobp.2022.12.017","volume":"116","author":"O Saifi","year":"2023","unstructured":"Saifi O, Breen WG, Lester SC, et al. Don\u2019t put the CART before the horse: the role of radiation therapy in peri-CAR T-cell therapy for aggressive b-cell non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2023;116:999\u20131007.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11837_CR27","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.ijrobp.2006.05.006","volume":"66","author":"EC Moser","year":"2006","unstructured":"Moser EC, Kluin-Nelemans HC, Carde P, et al. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin\u2019s lymphoma. Int J Radiat Oncol Biol Phys. 2006;66:1168\u201377.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11837_CR28","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/bmt.2008.408","volume":"43","author":"BS Hoppe","year":"2009","unstructured":"Hoppe BS, Moskowitz CH, Zhang Z, et al. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant. 2009;43:941\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"11837_CR29","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1200\/JCO.2009.27.3441","volume":"28","author":"J Phan","year":"2010","unstructured":"Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;28:4170\u20136.","journal-title":"J Clin Oncol"},{"key":"11837_CR30","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","volume":"32","author":"G Held","year":"2014","unstructured":"Held G, Murawski N, Ziepert M, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32:1112\u20138.","journal-title":"J Clin Oncol"},{"key":"11837_CR31","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2015.64.9418","volume":"34","author":"AK Ng","year":"2016","unstructured":"Ng AK, Dabaja BS, Hoppe RT, Illidge T, Yahalom J. Re-examining the role of radiation therapy for diffuse large B-cell lymphoma in the modern Era. J Clin Oncol. 2016;34:1443\u20137.","journal-title":"J Clin Oncol"},{"key":"11837_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJM199807023390104","volume":"339","author":"TP Miller","year":"1998","unstructured":"Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med. 1998;339:21\u20136.","journal-title":"N Engl J Med"},{"key":"11837_CR33","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1056\/NEJMoa042040","volume":"352","author":"F Reyes","year":"2005","unstructured":"Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352:1197\u2013205.","journal-title":"N Engl J Med"},{"key":"11837_CR34","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.2004.06.088","volume":"22","author":"SJ Horning","year":"2004","unstructured":"Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin\u2019s lymphoma: Eastern cooperative oncology group study 1484. J Clin Oncol. 2004;22:3032\u20138.","journal-title":"J Clin Oncol"},{"key":"11837_CR35","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1200\/JCO.2015.61.7654","volume":"33","author":"JA Vargo","year":"2015","unstructured":"Vargo JA, Gill BS, Balasubramani GK, Beriwal S. Treatment selection and survival outcomes in early-stage diffuse large B-Cell lymphoma: do we still need consolidative radiotherapy? J Clin Oncol. 2015;33:3710\u20137.","journal-title":"J Clin Oncol"},{"key":"11837_CR36","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.ijrobp.2008.02.068","volume":"72","author":"A Ballonoff","year":"2008","unstructured":"Ballonoff A, Rusthoven KE, Schwer A, et al. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys. 2008;72:1465\u201371.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11837_CR37","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3389\/fonc.2020.01157","volume":"10","author":"S Ma","year":"2020","unstructured":"Ma S, Zhang Y, Li Z, et al. Role of radiation therapy differs between stages in primary bone large B-cell lymphoma in rituximab era: a population-based analysis. Front Oncol. 2020;10:1157.","journal-title":"Front Oncol"},{"key":"11837_CR38","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/cncr.29113","volume":"121","author":"BS Dabaja","year":"2015","unstructured":"Dabaja BS, Vanderplas AM, Crosby-Thompson AL, et al. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the n ational c omprehensive C ancer N etwork lymphoma outcomes project. Cancer. 2015;121:1032\u20139.","journal-title":"Cancer"},{"key":"11837_CR39","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1182\/blood.2020005846","volume":"137","author":"CL Freeman","year":"2021","unstructured":"Freeman CL, Savage KJ, Villa DR, et al. Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2021;137:929\u201338.","journal-title":"Blood"},{"key":"11837_CR40","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ijrobp.2013.02.007","volume":"86","author":"Z Shi","year":"2013","unstructured":"Shi Z, Das S, Okwan-Duodu D, et al. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86:569\u201377.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11837_CR41","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ijrobp.2016.05.021","volume":"96","author":"S Dhakal","year":"2016","unstructured":"Dhakal S, Bates JE, Casulo C, et al. Patterns and timing of failure for diffuse large B-Cell lymphoma after initial therapy in a cohort who underwent autologous bone marrow transplantation for relapse. Int J Radiat Oncol Biol Phys. 2016;96:372\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11837_CR42","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.ijrobp.2021.06.038","volume":"111","author":"NB Figura","year":"2021","unstructured":"Figura NB, Robinson TJ, Sim AJ, et al. Patterns and predictors of failure in recurrent or refractory large B-Cell lymphomas after chimeric antigen receptor T-cell therapy. Int J Radiat Oncol Biol Phys. 2021;111:1145\u201354.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11837_CR43","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1182\/blood-2021-149702","volume":"138","author":"H Hubbeling","year":"2021","unstructured":"Hubbeling H, Silverman EA, Wijetunga NA, et al. Lesion Characteristics and Patterns of Failure in Diffuse Large B Cell Lymphoma Patients Treated with Bridging Radiotherapy Prior to Chimeric Antigen Receptor T Cell Therapy. Blood. 2021;138:1429\u20131429.","journal-title":"Blood"},{"key":"11837_CR44","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1182\/blood.2020006028","volume":"135","author":"J Yahalom","year":"2020","unstructured":"Yahalom J, Dabaja BS, Ricardi U, et al. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood. 2020;135:1829\u201332.","journal-title":"Blood"},{"key":"11837_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","volume":"89","author":"T Illidge","year":"2014","unstructured":"Illidge T, Specht L, Yahalom J, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2014;89:49\u201358.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11837_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-021-01122-1","volume":"14","author":"M Maerevoet","year":"2021","unstructured":"Maerevoet M, Zijlstra JM, Follows G, et al. Survival among patients with relapsed\/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. J Hematol Oncol. 2021;14:111.","journal-title":"J Hematol Oncol"},{"key":"11837_CR47","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1182\/blood.2020007512","volume":"137","author":"M Hamadani","year":"2021","unstructured":"Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137:2634\u201345.","journal-title":"Blood"},{"key":"11837_CR48","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1182\/blood.2021013289","volume":"139","author":"M Shadman","year":"2022","unstructured":"Shadman M, Pasquini M, Ahn KW, et al. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022;139:1330\u20139.","journal-title":"Blood"},{"key":"11837_CR49","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.26301","volume":"96","author":"JR Westin","year":"2021","unstructured":"Westin JR, Kersten MJ, Salles G, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96:1295\u2013312.","journal-title":"Am J Hematol"},{"key":"11837_CR50","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s00277-020-04342-6","volume":"100","author":"S Fuji","year":"2021","unstructured":"Fuji S, Kida S, Nakata K, Morishima T, Miyashiro I, Ishikawa J. Analysis of real-world data in patients with relapsed\/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era. Ann Hematol. 2021;100:2253\u201360.","journal-title":"Ann Hematol"},{"key":"11837_CR51","first-page":"4521","volume":"26","author":"Q Mei","year":"2020","unstructured":"Mei Q, Zhang W, Liu Y, et al. Camrelizumab plus gemcitabine, vinorelbine, and pegylated liposomal doxorubicin in relapsed\/refractory primary mediastinal b-cell lymphoma: a single-arm, open-label. Phase II Trial Clin Cancer Res. 2020;26:4521\u201330.","journal-title":"Phase II Trial Clin Cancer Res"},{"key":"11837_CR52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ijrobp.2014.09.041","volume":"91","author":"YD Tseng","year":"2015","unstructured":"Tseng YD, Chen YH, Catalano PJ, Ng A. Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015;91:223\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11837_CR53","doi-asserted-by":"crossref","unstructured":"Grignano E, Laurent J, Deau B, Burroni B, Bouscary D, Kirova YM. The role of radiotherapy as salvage and\/or consolidation treatment in relapsed\/refractory and high-risk diffuse large B-cell lymphoma. Eur J Haematol. 2018.","DOI":"10.1111\/ejh.13080"},{"key":"11837_CR54","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.12.005","volume":"100","author":"AK Ng","year":"2018","unstructured":"Ng AK, Yahalom J, Goda JS, et al. Role of radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2018;100:652\u201369.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11837_CR55","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","volume":"105","author":"AJ Sim","year":"2019","unstructured":"Sim AJ, Jain MD, Figura NB, et al. Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-Cell lymphoma. Int J Radiat Oncol Biol Phys. 2019;105:1012\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11837_CR56","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1182\/blood-2021-153739","volume":"138","author":"W Breen","year":"2021","unstructured":"Breen W, Young JR, Hathcock M, et al. Metabolic PET\/CT analysis of aggressive non-hodgkin lymphoma prior to axicabtagene ciloleucel CAR-t infusion: predictors of progressive disease, survival, and toxicity. Blood. 2021;138:2518\u20132518.","journal-title":"Blood"},{"key":"11837_CR57","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/ajh.26500","volume":"97","author":"HY Yhim","year":"2022","unstructured":"Yhim HY, Eshet Y, Metser U, et al. Risk stratification for relapsed\/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume. Am J Hematol. 2022;97:583\u201391.","journal-title":"Am J Hematol"},{"key":"11837_CR58","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1200\/JCO.21.02063","volume":"40","author":"NG Mikhaeel","year":"2022","unstructured":"Mikhaeel NG, Heymans MW, Eertink JJ, et al. Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: international metabolic prognostic index. J Clin Oncol. 2022;40:2352\u201360.","journal-title":"J Clin Oncol"},{"key":"11837_CR59","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.3324\/haematol.2021.280004","volume":"107","author":"C Rossi","year":"2022","unstructured":"Rossi C, Andre M, Dupuis J, et al. High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline. Haematologica. 2022;107:2897\u2013904.","journal-title":"Haematologica"},{"key":"11837_CR60","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1182\/blood.2022015423","volume":"139","author":"MG Mei","year":"2022","unstructured":"Mei MG, Lee HJ, Palmer JM, et al. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022;139:3605\u201316.","journal-title":"Blood"},{"key":"11837_CR61","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood.2019003127","volume":"135","author":"DJ Straus","year":"2020","unstructured":"Straus DJ, Dlugosz-Danecka M, Alekseev S, et al. Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 2020;135:735\u201342.","journal-title":"Blood"},{"key":"11837_CR62","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejca.2021.07.021","volume":"164","author":"N Lin","year":"2022","unstructured":"Lin N, Zhang M, Bai H, et al. Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: a multicenter, single-arm, phase II study. Eur J Cancer. 2022;164:117\u201326.","journal-title":"Eur J Cancer"},{"key":"11837_CR63","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nrclinonc.2016.30","volume":"13","author":"MB Bernstein","year":"2016","unstructured":"Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016;13:516\u201324.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-11837-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-11837-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-11837-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T08:03:06Z","timestamp":1705132986000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-11837-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,13]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["11837"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-11837-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3227917\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,13]]},"assertion":[{"value":"2 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All aspects of this study were reviewed and approved by the institutional review board of Fujian Medical University Union Hospital (2022WSJK019), which waived the requirement for signed informed consent because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}